Blood Advances · 2024 · 29 citations · 17 references
MedicineImmunologyPediatricsPediatric ImmunologyPediatric OncologyCancer RiskImmunotherapy SafetyT Cell BiologyAllogeneic Car T-cell TherapyAutologous Car T-cell TherapyCancer Risk In ChildrenInsertional MutagenesisInsertional Mutagenesis RiskPediatric Immunotherapy SafetySecondary Malignancy RiskSecondary Malignancy Surveillance
Our global survey reveals no cases of insertional mutagenesis following CAR T-cells in pediatric patients challenging concerns of secondary malignancy risk in this population.This underscores the safety of CAR T-cell therapy in this population, but ongoing surveillance required.
17
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Florian Zink, Simon Stacey, Gudmundur L. Norddahl et al. · Blood · 2017 · 789 citations · Full text
Life Sciences, Genetics, Hematology +14
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Kathryn M. Cappell, Richard M. Sherry, James C. Yang et al. · Journal of Clinical Oncology · 2020 · 308 citations · Full text
Medicine, Hematology, Oncology +16